RU2018131440A3 - - Google Patents

Download PDF

Info

Publication number
RU2018131440A3
RU2018131440A3 RU2018131440A RU2018131440A RU2018131440A3 RU 2018131440 A3 RU2018131440 A3 RU 2018131440A3 RU 2018131440 A RU2018131440 A RU 2018131440A RU 2018131440 A RU2018131440 A RU 2018131440A RU 2018131440 A3 RU2018131440 A3 RU 2018131440A3
Authority
RU
Russia
Application number
RU2018131440A
Other languages
Russian (ru)
Other versions
RU2018131440A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018131440A publication Critical patent/RU2018131440A/ru
Publication of RU2018131440A3 publication Critical patent/RU2018131440A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/203Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Composite Materials (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018131440A 2016-03-23 2017-03-23 Антагонисты FimH, являющиеся производными маннозы, пригодные для лечения заболевания RU2018131440A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662312017P 2016-03-23 2016-03-23
US62/312,017 2016-03-23
PCT/US2017/023764 WO2017165619A1 (en) 2016-03-23 2017-03-23 Mannose-derived antagonists of fimh useful for treating disease

Publications (2)

Publication Number Publication Date
RU2018131440A RU2018131440A (ru) 2020-04-23
RU2018131440A3 true RU2018131440A3 (enExample) 2020-05-18

Family

ID=59900869

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018131440A RU2018131440A (ru) 2016-03-23 2017-03-23 Антагонисты FimH, являющиеся производными маннозы, пригодные для лечения заболевания

Country Status (10)

Country Link
US (3) US10738070B2 (enExample)
EP (1) EP3432892A4 (enExample)
JP (1) JP2019509315A (enExample)
KR (1) KR20180128937A (enExample)
CN (1) CN108778288A (enExample)
AU (1) AU2017238392A1 (enExample)
BR (1) BR112018069147A2 (enExample)
CA (1) CA3018345A1 (enExample)
RU (1) RU2018131440A (enExample)
WO (1) WO2017165619A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018069147A2 (pt) 2016-03-23 2019-01-22 Fimbrion Therapeutics Inc composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh
US10385087B1 (en) * 2018-04-26 2019-08-20 National Taipei University Of Technology Xylose derivatives and process for preparation thereof
PL3820856T3 (pl) 2018-07-10 2022-12-19 Glaxosmithkline Intellectual Property Development Limited Związki c-mannozydów przydatne w leczeniu zakażeń układu moczowego
CN113795487B (zh) * 2019-05-07 2024-10-11 葛兰素史密斯克莱知识产权发展有限公司 新的化合物
US12351597B2 (en) * 2019-06-19 2025-07-08 Glaxosmithkline Intellectual Property Development Limited Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of FimH
CN111205344B (zh) * 2020-01-14 2023-03-14 华东理工大学 一种用于甲醇溶剂识别的纯有机磷光小分子材料及其制备方法
CN113461753B (zh) 2020-03-31 2023-05-23 郑计岳 2-炔基甘露糖衍生物及其应用
CN111518738B (zh) * 2020-05-08 2022-02-08 徐州海润生物科技有限公司 重组卡介苗及其制备方法和应用
CN113797212B (zh) * 2020-06-11 2023-12-22 兰州大学 一组含有甘露糖结构的抗菌药物的合成方法及活性研究
CN116621891B (zh) * 2023-05-25 2023-10-31 齐齐哈尔医学院 白鲜酚苷c及其制备方法和其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122602A (en) 1989-02-13 1992-06-16 Miles Inc. Chromogenic merocyanine enzyme substrates
DK0730601T3 (da) 1993-11-18 2005-06-06 Univ Washington Forbindelser og farmaceutiske præparater til behandling af profylakse af bakterieinfektioner
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
WO2001010386A2 (en) 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
CA2411944C (en) 2000-06-09 2010-12-14 Baylor College Of Medicine The combination of antimicrobial agents and bacterial interference to coat medical devices
AU2003274127A1 (en) 2003-10-08 2005-04-21 Innovaprotean, S.L. Compounds for the treatment of diseases associated with the formation of amyloid fibrils
EP1755619A2 (en) 2004-03-23 2007-02-28 VIB vzw Anti-adhesive compounds to prevent and treat bacterial infections
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
FR2876798A1 (fr) 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
EP3492483A1 (en) 2009-10-22 2019-06-05 The Washington University Compounds and methods for treating bacterial infections
NZ616764A (en) 2009-12-14 2014-11-28 Univ Basel Mannose derivatives as antagonists of bacterial adhesion
ES2732311T3 (es) * 2011-02-07 2019-11-21 Univ Washington Compuestos de manósidos y procedimientos de uso de los mismos
WO2012164074A1 (en) 2011-06-03 2012-12-06 University Of Basel Mannose phosphate derivatives as antagonists of bacterial adhesion
AU2014248717B2 (en) 2013-03-12 2018-03-29 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
EP3003322B1 (en) * 2013-05-30 2023-09-13 Washington University Mannose derivatives and their use in the treatment of bacterial infections
US20200002303A1 (en) 2016-03-11 2020-01-02 Fimbrion Therapeutics, Inc. C-glycoside compounds useful for treating disease
BR112018069147A2 (pt) 2016-03-23 2019-01-22 Fimbrion Therapeutics Inc composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh

Also Published As

Publication number Publication date
EP3432892A4 (en) 2019-10-30
US20250009723A1 (en) 2025-01-09
CA3018345A1 (en) 2017-09-28
AU2017238392A1 (en) 2018-09-27
US10738070B2 (en) 2020-08-11
US20200407390A1 (en) 2020-12-31
RU2018131440A (ru) 2020-04-23
KR20180128937A (ko) 2018-12-04
BR112018069147A2 (pt) 2019-01-22
WO2017165619A1 (en) 2017-09-28
US20190106451A1 (en) 2019-04-11
CN108778288A (zh) 2018-11-09
EP3432892A1 (en) 2019-01-30
JP2019509315A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
BR112018004682A2 (enExample)
BR112018003077A2 (enExample)
BR102016010174A2 (enExample)
BE2016C010I2 (enExample)
CN303564749S (enExample)
CN303539345S (enExample)
CN303618737S (enExample)
CN303603505S (enExample)
CN303596505S (enExample)
CN303591658S (enExample)
CN303584520S (enExample)
CN303576628S (enExample)
CN303538069S (enExample)
CN303563834S (enExample)
CN303553153S (enExample)
CN303543667S (enExample)
CN303539447S (enExample)
CN303539429S (enExample)
CN303539396S (enExample)
CN303539038S (enExample)
CN303539312S (enExample)
CN303539116S (enExample)
CN303539115S (enExample)
CN303539089S (enExample)
CN303539084S (enExample)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210225